Then we analyzed the levels of FOXP2 expression in the clinical breast cancer samples (n=394) from TCGA (Supplementary Table) and found that the levels of FOXP2 in all four breast cancer subgroups (Basal, Her2, LumA, and LumB) were lower than that in the normal group (Figure 1G). This evidence concerns the gene FOXP2 and breast cancer.